Bassil Dahiyat, PhD

President and CEO at Xencor

Speaker

Bassil Dahiyat has been Xencor’s president and chief executive officer since the Company’s incorporation in August 1997. He has led the Company in creating a diverse portfolio of engineered antibodies and cytokines for the treatment of life-threatening and debilitating diseases, and has established alliances with leading biopharmaceutical companies that have resulted in three marketed drugs and the broad use of Xencor's XmAb engineering technology around the industry. Dr. Dahiyat has co-authored numerous scientific papers in the fields of protein design and drug delivery, is an inventor of over 30 U.S. and numerous foreign patents and has received scientific awards from the American Chemical Society, the Controlled Release Society, the Protein Society and Caltech. Dr. Dahiyat also serves as a member of the board of directors of Kodiak Sciences and Terray Therapeutics. He holds a Ph.D. in Chemistry from Caltech and B.S. and M.S.E. degrees in Biomedical Engineering from the Johns Hopkins University.